IGF and Other Neurotrophic Factors in Patients With Dementia

NCT02271750 | Completed DMC

• 2 other identifiers: Dementia IGF1-10-72-250-14
• Study Type: observational
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

The global prevalence of dementia is close to 36 million (2010). Furthermore the number is predicted to double in the next 20 years, primarily due to the demographic ageing. A perspective that will challenge the current healthcare systems and national economies. Dementia is characterized by progressive deterioration in cognition, function and behavior that is sufficiently severe to compromise social and occupational functioning. The pathogenesis of dementia remains elusive. Thus, there is a need to increase our understanding of the mechanisms leading to the most common forms of dementia. A better understanding of the disease may enable an earlier diagnosis and importantly, a causal treatment of Alzheimer as opposed to the merely symptomatic options available to day. An experiment with rats and memory might already have taken the first step towards this. The experiment has demonstrated that administration of IGF-II to rats significantly enhances memory retention and prevents forgetting. Furthermore inhibitory avoidance learning leads to an increase in the hippocampal expression of IGF-II. Finally, yet importantly, injections of recombinant IGF-II into hippocampus after training or memory retrieval significantly enhance memory retention and prevent forgetting. The spinal fluid and the serum will be analysed at the Medical Research Laboratory. The immunological concentrations of IGF-I and -II are measured by validated in-house analyses. Furthermore, Aarhus University Hospital has a unique technique, whereby it is possible to measure the bioactivity of IGF-I and -II in the cerebrospinal fluid. The concentrations of NGF, BDNF and sCD-163 in spinal fluid and serum will be analysed by already established techniques. The purpose of this study is therefore to define the concentration and biological activity of IGF-I, IGF-II, BDNF, NGF and sCD-163 in the cerebrospinal fluid and serum in patients with Alzheimer's compared with controls.

Conditions

Dementia

Keywords

IGF, Neurotrophic factors, Dementia, spinal fluid

Outcome Measures

Primary Outcomes (5)

• Concentration and/or activity of IGF-I in cerebrospinal fluid.

  People with dementia compared with controls

  day 1

• Concentration and/or activity of IGF-II in cerebrospinal fluid.

  People with dementia compared with controls

  day 1

• Concentration of NGF in cerebrospinal fluid.

  People with dementia compared with controls

  day 1

• Concentration of BDNF in cerebrospinal fluid.

  People with dementia compared with controls

  day 1

• Concentration of sCD163 in cerebrospinal fluid.

  People with dementia compared with controls

  day 1

Study Arms (2)

Dementia

Procedure: lumbar puncture

controls

Procedure: lumbar puncture

Interventions

lumbar puncture PROCEDURE

for spinal fluid

Dementia; controls

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

dementia

You may qualify if:

• dementia, controls(lumbar puncture at our department)

You may not qualify if:

• \<18år
• other CNS disease

Sponsors & Collaborators

• University of Aarhus: lead

Study Sites (1)

Department of Neurology

Aarhus C, 8000, Denmark

Location

Related Publications (12)

• Holmes, Clive: Dementia: Medicin(United Kingdom), 2012, Vol. 40, part 11, p. 628-631

  BACKGROUND

• Georges J, Jansen S, Jackson J, Meyrieux A, Sadowska A, Selmes M. Alzheimer's disease in real life--the dementia carer's survey. Int J Geriatr Psychiatry. 2008 May;23(5):546-51. doi: 10.1002/gps.1984.

  PMID: 18232054 BACKGROUND

• Luque FA, Jaffe SL. The molecular and cellular pathogenesis of dementia of the Alzheimer's type an overview. Int Rev Neurobiol. 2009;84:151-65. doi: 10.1016/S0074-7742(09)00408-5.

  PMID: 19501717 BACKGROUND

• Bertram L. Alzheimer's disease genetics current status and future perspectives. Int Rev Neurobiol. 2009;84:167-84. doi: 10.1016/S0074-7742(09)00409-7.

  PMID: 19501718 BACKGROUND

• Hampel H, Lista S, Teipel SJ, Garaci F, Nistico R, Blennow K, Zetterberg H, Bertram L, Duyckaerts C, Bakardjian H, Drzezga A, Colliot O, Epelbaum S, Broich K, Lehericy S, Brice A, Khachaturian ZS, Aisen PS, Dubois B. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. Biochem Pharmacol. 2014 Apr 15;88(4):426-49. doi: 10.1016/j.bcp.2013.11.009. Epub 2013 Nov 22.

  PMID: 24275164 BACKGROUND

• Chen DY, Stern SA, Garcia-Osta A, Saunier-Rebori B, Pollonini G, Bambah-Mukku D, Blitzer RD, Alberini CM. A critical role for IGF-II in memory consolidation and enhancement. Nature. 2011 Jan 27;469(7331):491-7. doi: 10.1038/nature09667.

  PMID: 21270887 BACKGROUND

• de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol. 2008 Nov;2(6):1101-13. doi: 10.1177/193229680800200619.

  PMID: 19885299 BACKGROUND

• Hoyer S. Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Adv Exp Med Biol. 2004;541:135-52. doi: 10.1007/978-1-4419-8969-7_8.

  PMID: 14977212 BACKGROUND

• Bloemer J, Bhattacharya S, Amin R, Suppiramaniam V. Impaired insulin signaling and mechanisms of memory loss. Prog Mol Biol Transl Sci. 2014;121:413-49. doi: 10.1016/B978-0-12-800101-1.00013-2.

  PMID: 24373245 BACKGROUND

• Trueba-Saiz A, Cavada C, Fernandez AM, Leon T, Gonzalez DA, Fortea Ormaechea J, Lleo A, Del Ser T, Nunez A, Torres-Aleman I. Loss of serum IGF-I input to the brain as an early biomarker of disease onset in Alzheimer mice. Transl Psychiatry. 2013 Dec 3;3(12):e330. doi: 10.1038/tp.2013.102.

  PMID: 24301648 BACKGROUND

• Sopova K, Gatsiou K, Stellos K, Laske C. Dysregulation of neurotrophic and haematopoietic growth factors in Alzheimer's disease: from pathophysiology to novel treatment strategies. Curr Alzheimer Res. 2014 Jan;11(1):27-39. doi: 10.2174/1567205010666131120100743.

  PMID: 24251394 BACKGROUND

• Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007 Jul;3(3):186-91. doi: 10.1016/j.jalz.2007.04.381.

  PMID: 19595937 BACKGROUND

Related Links

• About dementia: Alzheimer's disease association

Biospecimen

Retention: SAMPLES WITHOUT DNA

spinal fluid and blood sample for identification of different factors

MeSH Terms

Conditions

Dementia

Interventions

Spinal Puncture

Condition Hierarchy (Ancestors)

Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Biopsy; Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Diagnostic Techniques, Neurological; Punctures; Therapeutics; Surgical Procedures, Operative; Investigative Techniques

Study Design

• Study Type: observational
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 2, 2014
• First Posted: October 22, 2014
• Study Start: October 1, 2014
• Primary Completion: November 1, 2015
• Last Updated: December 8, 2015

Record last verified: 2014-10

Locations

DK (1)